| Authors: |
Barrodia P; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.; Department of Genomic Medicine and MDACC Epigenomics Therapy Initiative, The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Saw AK; Department of Genomic Medicine and MDACC Epigenomics Therapy Initiative, The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Jeter-Jones SL; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Chang CC; Department of Genomic Medicine and MDACC Epigenomics Therapy Initiative, The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Shao J; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Arslan E; Department of Genomic Medicine and MDACC Epigenomics Therapy Initiative, The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Singh AK; Department of Genomic Medicine and MDACC Epigenomics Therapy Initiative, The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Satpati S; Department of Genomic Medicine and MDACC Epigenomics Therapy Initiative, The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Jenq RR; Department of Genomic Medicine and MDACC Epigenomics Therapy Initiative, The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Rai K; Department of Genomic Medicine and MDACC Epigenomics Therapy Initiative, The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Piwnica-Worms H; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030. |
